BMS' Opdivo-Yervoy duo nears its shot in first-line lung cancer with FDA 'priority' boost

15th January 2020 Uncategorised 0

Bristol-Myers Squibb has been waiting years to get a crack at the previously untreated non-small cell lung cancer market, but the end to its waiting may finally be in sight. And with an FDA priority review to speed things up, that wait could be mercifully short.

More: BMS' Opdivo-Yervoy duo nears its shot in first-line lung cancer with FDA 'priority' boost
Source: fierce